CFM
VNDA icon

Catalyst Funds Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Catalyst Funds Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$23 – 1621
2024
Q2 		$23 Sell
4
-18
-82% -$93 ﹤0.01% 1141
2024
Q1 		$90 Buy
+22
New +$88 ﹤0.01% 1086

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's VNDA Position: Q3 2024 in Review

Catalyst Funds Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 4 shares — an estimated $23 sold.

Catalyst Funds Management first reported a position in VNDA in Q1 2024 and held it in 2 quarters. The position peaked at $90 in Q1 2024. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

  • Catalyst Funds Management reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 4 Vanda Pharmaceuticals shares in Q3 2024, an estimated $23.
  • Catalyst Funds Management first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Vanda Pharmaceuticals position peaked at $90 in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.